A widely-used class of cholesterol-lowering drugs produces a metabolic byproduct with documented antiviral activity against rhinovirus — yet no study has connected the two for cold treatment. The mechanism is well-characterised in cholesterol biology; its application here has never been tested.
Full mechanistic analysis available under commercial agreement.
Request AccessA self-amplifying inflammatory cycle links gut-derived signals to misfolded protein accumulation in the brain, each reinforcing the other. Combining an anti-inflammatory approved for another indication with a drug that enhances a specific sleep-dependent clearance process could interrupt the cycle at two independent points — a combination never tested.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific form of iron-dependent cell death damages the receptor responsible for clearing amyloid from the brain, creating a self-reinforcing cycle of accumulation. Combining an approved iron-chelating drug with a receptor-targeted approach addresses both sides of this cycle — the first demonstration of this connection.
Full mechanistic analysis available under commercial agreement.
Request AccessPairing a cholesterol-pathway antiviral approach with an intranasal bacterial lysate that primes local immunity, stratified by individual microbiome risk profiles, targets both viral replication and host defence simultaneously — a combination of immediately actionable, already-approved components.
Full mechanistic analysis available under commercial agreement.
Request AccessA non-invasive therapeutic technique demonstrates the ability to actively promote nerve repair in MS lesions, offering potential disease-modifying benefit beyond current symptom management approaches.
Full mechanistic analysis available under commercial agreement.
Request AccessA common dysfunction has been identified as a shared pathway across several distinct chronic pain conditions. A drug already approved for a cardiac indication, with a relevant secondary channel-modulating property, could be repurposed to target this shared mechanism across multiple pain syndromes at once.
Full mechanistic analysis available under commercial agreement.
Request AccessFirst proposal to combine two glucose-lowering mechanisms with different temporal profiles specifically in pediatric Type 1 diabetes, aiming to prevent downstream cardiovascular-kidney-metabolic complications in younger patients.
Full mechanistic analysis available under commercial agreement.
Request AccessFirst demonstration that a specific mitochondrial stress biomarker correlates with HIV reservoir persistence independent of inflammation. Targeting cellular metabolism through this pathway represents a novel cure strategy beyond traditional antiviral and immune-activation approaches.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved metabolic drug suppresses the cytokine storm response responsible for severe influenza mortality. Combining it with a standard antiviral targets both viral replication and the host immune overreaction simultaneously — a dual-mechanism approach with zero prior investigation.
Full mechanistic analysis available under commercial agreement.
Request AccessHSV establishes lifelong latency through epigenetic silencing. An epigenetic-modifying drug could force the latent virus into active replication, making it vulnerable to a specific antiviral — a strategy that could eliminate the reservoir entirely rather than just suppressing outbreaks.
Full mechanistic analysis available under commercial agreement.
Request AccessAn FDA-approved antiparasitic disrupts cancer cell structure through the same mechanism as established chemotherapy agents, but with a dramatically superior safety profile. Cross-condition analysis reveals synergy with immune checkpoint inhibitors, potentially sensitising resistant tumours to immunotherapy.
Full mechanistic analysis available under commercial agreement.
Request AccessLupus patients show selective, rather than global, immune dysfunction against influenza vaccines. A temporary pause in a specific B-cell-depleting biologic before vaccination could allow immune recovery and dramatically improve vaccine response in this high-mortality population.
Full mechanistic analysis available under commercial agreement.
Request AccessA rare HSV neurological complication in HIV patients may be severely underdiagnosed due to clinician bias. An immune modulator with a documented dual role — suppressing autoimmune inflammation while enhancing antiviral immunity — combined with standard antiviral therapy represents a completely unexplored treatment strategy.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific iron-dependent cell death process is emerging as a central mechanism in Parkinson's neurodegeneration. An investigational nanoparticle approach combined with an approved iron chelator targets both systemic and local drivers of this process — never previously attempted in Parkinson's.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved antiepileptic and an approved sedative each independently address different hallmark pathologies of Alzheimer's disease — and have never been tested in combination. Both cross the blood-brain barrier with decades of established safety data, enabling a trial within 12 months.
Full mechanistic analysis available under commercial agreement.
Request AccessCombining a cholesterol-pathway antiviral approach with an intranasal immune-priming agent that bypasses the limitations of oral delivery attacks both viral replication and host immune defence simultaneously.
Full mechanistic analysis available under commercial agreement.
Request AccessHIV treatment failure is driven less by regimen complexity than by a specific, distinct psychological barrier around medication-taking behaviour. An approved antidepressant with a relevant mechanism could directly address this neurobiological pathway.
Full mechanistic analysis available under commercial agreement.
Request AccessA next-generation opioid selectively activates the pain-relief signalling pathway while avoiding the pathway responsible for respiratory depression and addiction. Combined with AI-driven real-time dosage optimisation, this could deliver effective chronic pain management without the danger that makes traditional opioids so risky.
Full mechanistic analysis available under commercial agreement.
Request AccessA chronic pelvic pain condition has a 90%+ treatment failure rate with current therapies. A specific inflammatory signalling molecule directly excites pain nerves through a pathway completely independent of inflammation itself. An approved anti-inflammatory biologic class could work as a direct analgesic — not by reducing inflammation, but by blocking nerve excitation at its source. Zero clinical trials have ever tested this despite clear mechanistic evidence.
Full mechanistic analysis available under commercial agreement.
Request AccessTwo immune cell types actively amplify each other's damage in MS through a bidirectional feedback loop. An approved antibiotic with an unrelated primary use could break this loop when combined with standard disease-modifying therapy. Separately, current MS dosing is identical regardless of age or sex despite documented metabolic differences — a correctable error causing over- and under-dosing.
Full mechanistic analysis available under commercial agreement.
Request AccessPatients with a specific chronic liver condition show paradoxically enhanced vaccine responses due to elevated baseline inflammation. An approved gut-modulating antibiotic could deliberately pre-condition this inflammatory state before vaccination to optimise antibody production — inverting the standard assumption that inflammation impairs vaccine efficacy.
Full mechanistic analysis available under commercial agreement.
Request AccessAn FDA-approved COVID-19 antiviral targets an enzyme structurally homologous to one essential for rhinovirus replication. Zero studies have tested this despite the mechanistic overlap being directly demonstrable from structural data. A second, independently-acting antifungal agent offers additional combination potential.
Full mechanistic analysis available under commercial agreement.
Request AccessA neuropeptide driving migraine pain is now identified as a significant contributor to endometriosis-associated pelvic pain. An approved migraine biologic has never been tested in endometriosis despite targeting the same underlying pathway. A non-pharmacological nerve stimulation technique offers a complementary approach — a combination with zero prior research.
Full mechanistic analysis available under commercial agreement.
Request AccessLupus-related kidney damage has a newly identified mechanism distinct from the classical immune-complex model. An approved, widely available antioxidant compound directly inhibits this specific cell death cascade. Prior trials of this compound targeted oxidative stress generally — none have tested this specific mechanistic rationale.
Full mechanistic analysis available under commercial agreement.
Request AccessPeanut oral immunotherapy achieves desensitisation, but sustained remission remains elusive. Three mechanistically non-overlapping interventions — a biologic, a specific probiotic strain, and standard OIT — have each been tested individually or in pairs, but never all three together, despite acting through completely independent pathways.
Full mechanistic analysis available under commercial agreement.
Request AccessResistance mutations selected by one antiretroviral paradoxically increase susceptibility to a second, confirmed by structural imaging. This inverts the standard resistance-response paradigm — rather than abandoning the second drug when resistance emerges, intensifying its use could exploit this collateral sensitivity. Zero prior clinical exploitation of this mechanism.
Full mechanistic analysis available under commercial agreement.
Request AccessA drug approved for autoimmune disease and transplant rejection blocks one immune activation pathway, while a distinct T-cell engaging cancer therapy activates T-cells through a completely separate route — bypassing the blockade entirely. The two can be co-administered without sacrificing anti-tumour efficacy. Both approved. Zero prior trials combining them.
Full mechanistic analysis available under commercial agreement.
Request AccessLupus autoantibodies cross-react with a specific brain receptor via molecular mimicry, causing neuronal damage and the cognitive dysfunction that defines neuropsychiatric lupus. An approved Alzheimer's drug directly blocks the same receptor subtype, crosses the blood-brain barrier reliably, and has an established safety profile. Zero clinical trials despite 20 years of mechanistic evidence.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific psoriasis biologic's known infection risk is not a side effect — it is a pharmacodynamic inevitability of its mechanism, with published data identifying specific peak-risk time windows. Time-limited prophylaxis with an approved antifungal during these windows, rather than continuous or reactive treatment, has never been systematically studied despite being entirely predictable from the drug's known pharmacology.
Full mechanistic analysis available under commercial agreement.
Request AccessAdults are underserved by peanut oral immunotherapy because dose-related reaction rates are substantially higher than in children, driving dropout. An approved biologic, restricted specifically to the updosing phase, could preserve the tolerogenic immune response while suppressing the dangerous reactions that cause abandonment. No completed trial exists for this specific application in adults.
Full mechanistic analysis available under commercial agreement.
Request AccessA drug class already approved for diabetes, heart failure, and kidney disease has been identified for two distinct, unexplored indications — one via causal genetic evidence for a completely unrelated metabolic condition, the other for limb preservation following a specific vascular procedure where current amputation rates remain unacceptably high with no approved pharmacotherapy.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific programmed cell death pathway continuously releases material that triggers the type I interferon burst driving the entire lupus autoimmune cascade. Current treatments suppress this cascade downstream. An investigational inhibitor already has Phase II safety data in a different autoimmune condition, yet zero registered lupus trials exist despite the mechanistic logic being fully mapped.
Full mechanistic analysis available under commercial agreement.
Request AccessChildren under six represent the highest remission potential window for peanut oral immunotherapy. A biologic that prevents new IgE generation, rather than only neutralising existing IgE, offers a mechanistically distinct approach in this age group. No published trial exists for this specific combination despite the biologic being approved from six months of age.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved antimalarial attacks drug-resistant HSV through two completely independent pathways simultaneously, bypassing the resistance mechanisms that cause standard antivirals to fail. For millions of patients with resistant HSV, this could be the first genuinely new treatment option in decades.
Full mechanistic analysis available under commercial agreement.
Request AccessEndometriosis causes chronic pelvic pain through fibrotic scar-like tissue that medicine has largely failed to treat. An approved blood pressure medication class has well-documented anti-fibrotic effects in other organs via a shared pathway. This same mechanism could directly target adhesion formation driving endometriosis pain. Zero studies have tested this despite a mechanistically strong fit.
Full mechanistic analysis available under commercial agreement.
Request AccessHIV patients on antiretroviral therapy develop a premature ageing syndrome driven by mitochondrial dysfunction and accumulated aged cells causing systemic damage. A metabolic supplement restores mitochondrial function while a senolytic combination clears the accumulated aged cells. This triple approach addresses both cause and consequence — never studied together in HIV patients.
Full mechanistic analysis available under commercial agreement.
Request AccessA catastrophic diabetic complication causes spontaneous bone collapse through uncontrolled inflammatory destruction. An approved osteoporosis drug directly blocks the pathway driving this overactivation. In a hormonally deficient subgroup, concurrent hormone replacement restores the balance that normally protects bone. This dual mechanism has never been studied despite both pathways being independently documented.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific sequential pathway links environmental toxin exposure to sustained neuroinflammation in Parkinson's. An approved cancer drug that crosses the blood-brain barrier blocks a critical node in this cascade. Combined with a structured rehabilitation protocol, this could simultaneously reduce neuroinflammation and enhance motor learning.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved B-cell depleting biologic excels at preventing new MS lesions but cannot repair existing damage. A non-invasive brain stimulation technique promotes repair through neuroplasticity mechanisms that address exactly this gap. Combining the two targets both disease processes simultaneously — zero prior research despite the logic being immediately apparent.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific immune cell subset is disproportionately enriched in the latent HIV reservoir. An approved HIV entry inhibitor, normally used for a different purpose, may selectively deplete these reservoir-maintaining cells — actively shrinking the reservoir rather than merely preventing new infection. This inverts the drug's standard understood role. Zero trials have tested this specific hypothesis.
Full mechanistic analysis available under commercial agreement.
Request AccessSix consecutive weeks of convergent signals across independent research groups have identified small molecule candidates capable of restoring limited cardiac regeneration capacity without viral vector delivery. Adult heart muscle cannot normally divide, making heart attack damage permanent — this approach transiently restores that capacity without the oncogenic risk of earlier reprogramming methods. Multiple independent groups are converging on the same mechanism without coordination.
Full mechanistic analysis available under commercial agreement.
Request AccessA commercially significant metabolic drug is identified for Alzheimer's via a direct signalling mechanism in brain immune cells — suppressing neuroinflammation and promoting a neuroprotective cellular state. This is mechanistically distinct from a related drug's already-tested approach, due to superior brain penetration. No completed trial exists for this specific drug in Alzheimer's despite a related trial establishing the broader drug class as a credible target.
Full mechanistic analysis available under commercial agreement.
Request AccessA targeted cancer drug, approved for a mutation-defined tumour type, could apply directly to a genetically identical mutation subtype in a different cancer with no approved targeted therapy of its own. The mechanistic bridge is direct — same drug, same mutation class, different tumour. Zero clinical trials exist despite the mechanistic rationale requiring no additional preclinical validation.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved addiction treatment drug has a unique receptor activity profile distinct from related drugs in its class, with anti-neuroinflammatory effects directly relevant to central sensitisation — the shared pathological substrate across several chronic overlapping pain conditions. Zero pain trials exist despite this receptor profile potentially being superior to existing approaches.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved cardio-metabolic drug class, already indicated for established heart failure, could be applied earlier — in the pre-symptomatic window where structural cardiac damage accumulates before a formal diagnosis exists. Its cardioprotective mechanisms operate independently of glycaemic control, making early intervention mechanistically justified.
Full mechanistic analysis available under commercial agreement.
Request AccessA widely available, decades-old OTC drug stabilises a specific misfolded protein linked to the most common known genetic risk factor for Parkinson's, affecting a meaningful proportion of patients. Proof-of-concept trial data already exists. The drug remains unlicensed for this use despite established safety data and a directly validated mechanistic target — a classic repurposing gap where commercial incentives have failed to drive regulatory development.
Full mechanistic analysis available under commercial agreement.
Request AccessA generic drug costing pennies per pill, with a 30+ year safety record, shows direct neuroprotection in progressive MS via a mechanism distinct from all approved disease-modifying therapies, which target inflammation. A major trial demonstrated significant reduction in brain atrophy. No regulatory submission has been made despite positive clinical data — the defining example of a repurposing gap where generic drug economics prevent development of a proven treatment.
Full mechanistic analysis available under commercial agreement.
Request AccessEndometriotic lesions exhibit a cancer-like metabolic shift that allows them to survive and proliferate in hostile locations. An investigational compound with established safety data from rare metabolic disorder trials could selectively impair lesion survival without affecting normal tissue. Zero endometriosis trials exist despite the metabolic parallel being directly demonstrable from published data.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved drug, used at a much lower dose than its standard indication, acts through a completely distinct mechanism to suppress the post-viral neuroinflammatory cascade characterising Long COVID's neurological symptoms. Long COVID's neuroinflammatory substrate is now well characterised by imaging. No properly powered trial exists despite widespread off-label use and extensive mechanistic rationale.
Full mechanistic analysis available under commercial agreement.
Request AccessCell-permeable forms of a naturally occurring immune metabolite redirect immune cell metabolism toward an anti-inflammatory state through a mechanism entirely distinct from all approved RA biologics, which target cytokine signalling downstream. Zero clinical trials exist despite compelling preclinical data from multiple independent groups.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved psoriasis drug uses an allosteric mechanism to inhibit a signalling node sitting at the convergence of three distinct pathological pathways simultaneously driving lupus kidney disease. This selectivity avoids safety concerns that have complicated related drug classes in autoimmune disease. Phase II data supports efficacy in broader lupus; the specific kidney application remains untested.
Full mechanistic analysis available under commercial agreement.
Request AccessA biologic approved for other Type 2 inflammatory conditions is identified for a biomarker-definable COPD subgroup representing 25-30% of patients. Trial data supports efficacy. The precise patient selection criterion is the novel finding that defines who responds — resolving why previous undifferentiated trial designs have consistently failed in this heterogeneous disease.
Full mechanistic analysis available under commercial agreement.
Request AccessA drug approved for two specific rare epilepsy syndromes directly modulates the exact channel function affected in a related channelopathy, via a distinct receptor mechanism. This is a mechanistically grounded extension into an adjacent genetic epilepsy with a directly demonstrable molecular overlap. Zero trials exist despite the established safety profile and direct molecular connection.
Full mechanistic analysis available under commercial agreement.
Request AccessA drug approved for related inflammatory conditions is identified specifically for a Crohn's disease subtype mechanistically distinct from the more common form, and currently excluded from the drug's own development programme for the disease broadly. Its specific signalling profile is mechanistically better suited to this subtype than agents being developed more broadly. Zero subtype-specific trials exist.
Full mechanistic analysis available under commercial agreement.
Request AccessA low-dose repurposing of an approved drug suppresses chronic neuroinflammation underlying post-exertional malaise, the defining and most debilitating ME/CFS symptom, via a mechanism distinct from its standard-dose use. Neuroinflammation is now measurable by imaging, providing a validated biomarker endpoint. No properly powered trial exists despite compelling rationale and an inexpensive, accessible intervention.
Full mechanistic analysis available under commercial agreement.
Request AccessA selectively-acting biologic, approved for a different allergic condition, is identified as a peanut OIT adjunct — mechanistically distinct from a broader-acting biologic already discussed in this series. The selective mechanism could reduce adverse events and dropout while preserving the specific signal underlying durable tolerance. Zero OIT trials exist for this application despite the mechanistic distinction being derivable from established cytokine biology.
Full mechanistic analysis available under commercial agreement.
Request AccessA devastating HSV complication carries high untreated mortality even with standard treatment. A drug approved elsewhere targets a different viral enzyme complex, retaining full antiviral activity against strains resistant to first-line therapy — a growing clinical problem with no approved alternative. Zero condition-specific trials exist for this drug class.
Full mechanistic analysis available under commercial agreement.
Request AccessOne tree nut allergen binds immune cells with exceptional affinity, producing higher reaction and dropout rates than peanut allergy during OIT. A biologic that reduces the immune priming driving this severity uses the identical pathway already implicated in peanut allergy — a direct mechanistic transfer. Zero tree nut-specific trials exist for this combination.
Full mechanistic analysis available under commercial agreement.
Request AccessA low-dose repurposing of an approved drug is identified for chronic pain neuroinflammation, paired with a validated imaging biomarker enabling both patient selection and response monitoring. This transforms a previously speculative off-label intervention into a hypothesis with a defined selection criterion and objective endpoint. Never trialled in primary chronic pain with this biomarker as the primary endpoint.
Full mechanistic analysis available under commercial agreement.
Request AccessA defined sequential protocol targets two compartments of progressive MS inflammation — one biologic depletes peripheral immune cells first, then a second, brain-penetrant agent addresses compartmentalised inflammation the first cannot reach. This sequencing avoids immunosuppression overlap and makes trial design immediately practical. Both drugs approved. Zero studies have tested this specific sequential protocol.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific inflammatory signature is elevated in a definable, majority RA patient subgroup. An approved psoriasis drug's allosteric mechanism sits directly upstream of this signature, making it mechanistically precise for this subgroup. The biomarker-stratified design enables an immediately actionable trial. Zero RA trials exist for this drug class despite the pathway being directly implicated in seropositive disease.
Full mechanistic analysis available under commercial agreement.
Request AccessOne approved drug induces rapid remission via broad systemic activity; a second then maintains remission via gut-selective action without systemic immunosuppression. The sequential design exploits each drug's strength at the right phase. Both approved for inflammatory bowel disease. Zero studies have tested this specific sequential protocol despite the complementary mechanisms being directly derivable from established pharmacology.
Full mechanistic analysis available under commercial agreement.
Request AccessA biologic approved for severe asthma blocks the very first epithelial alarm signal that initiates the entire allergic cascade, before any downstream immune signalling begins. As an OIT adjunct, this targets the cascade upstream of where existing adjuncts act — preventing reactions at their source rather than managing them downstream. Zero peanut OIT trials exist for this drug despite the pathway being well established in food allergy sensitisation.
Full mechanistic analysis available under commercial agreement.
Request AccessSeven consecutive weeks of convergent signals across independent research groups have confirmed small molecule candidates capable of restoring limited cardiac regeneration capacity without viral delivery. Two specific compound classes are now emerging across multiple independent groups without coordination — the convergence pattern that precedes genuine pre-clinical breakthrough.
Full mechanistic analysis available under commercial agreement.
Request AccessA repurposing candidate for a genetically-defined Parkinson's subgroup now has a fully actionable precision medicine trial design — genetic status as selection criterion, a specific enzyme activity as pharmacodynamic endpoint, and a validated disease marker as secondary endpoint. Proof-of-concept trial data exists. No regulatory submission has been made despite the complete trial design being immediately available.
Full mechanistic analysis available under commercial agreement.
Request AccessSub-anaesthetic microdosing of an approved anaesthetic is identified for resetting central pain sensitisation — transiently disrupting the maladaptive synaptic changes that maintain chronic pain hypersensitivity. A specific short repeated low-dose protocol produces durable effects without the drug's typical dissociative properties. No trial has tested this specific protocol with sensitisation reset as the primary target and neuroinflammatory imaging as a companion biomarker.
Full mechanistic analysis available under commercial agreement.
Request AccessA drug approved for metabolic liver disease acts on a receptor pathway also expressed in endometriotic lesions, which exhibit lipid metabolic dysregulation identical to the hepatic mechanism the drug addresses. This offers a metabolic approach to endometriosis entirely distinct from current hormonal treatments, which suppress the hormonal environment rather than lesion metabolism directly. Zero endometriosis trials exist for this drug class.
Full mechanistic analysis available under commercial agreement.
Request AccessA biologic identified for psoriatic arthritis patients who have failed a related, single-target biologic class. A second inflammatory pathway continues driving joint damage in these patients through a route the single-target agents cannot block. The dual-target biologic addresses this residual pathway. Prior treatment failure defines an immediately actionable trial population. Zero studies have tested this specific sequencing strategy.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific antiviral pathway defect is measurable and defines a distinct ME/CFS subtype driven by innate immune dysregulation. Earlier trials of an investigational immune modulator showed modest signals in unselected populations — the key gap is that biomarker-stratified trial design using this defect as a selection criterion has never been conducted, despite being mechanistically distinct from other approaches in this series.
Full mechanistic analysis available under commercial agreement.
Request AccessTwo specific food allergies frequently co-occur, making sequential treatment burdensome and prolonged. A broad-acting biologic reduces reactivity across multiple allergens simultaneously, enabling concurrent multi-food desensitisation protocols that would otherwise carry unacceptable risk. A major trial established multi-food proof of concept, but the specific co-occurring combination addressed here has not been evaluated as a defined trial endpoint.
Full mechanistic analysis available under commercial agreement.
Request AccessAllergen exposure during tree nut OIT dose escalation triggers an epithelial alarm signal that initiates the allergic cascade, driving exceptionally high dropout rates. Blocking this signal upstream, before dose escalation begins, prevents the cascade at its source. The severity profile of the tree nut allergen involved makes the case for this upstream approach even stronger than the equivalent peanut finding identified previously. Zero tree nut-specific trials exist.
Full mechanistic analysis available under commercial agreement.
Request AccessA hypertension drug is uniquely positioned among its class as the only one with documented blood-brain barrier penetration at relevant concentrations. Inside the brain, it suppresses neuroinflammation in a region central to Parkinson's pathology via a dual mechanism independent of its cardiovascular role. Zero Parkinson's trials exist despite this penetration being the key pharmacological differentiator from every related drug in clinical use.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved RA drug induces selective oxidative stress in HIV-infected cells, which carry additional metabolic burden from active viral replication machinery, making them more vulnerable than uninfected cells. This exploits a differential vulnerability to selectively deplete reservoir-harbouring cells without broad immune damage — a second, mechanistically distinct reservoir reduction approach alongside others in this archive. Zero reservoir-specific trials exist for this drug.
Full mechanistic analysis available under commercial agreement.
Request AccessTwo approved drugs target central sensitisation through non-overlapping mechanisms — one suppresses upstream neuroinflammation, the other blocks the downstream synaptic changes that maintain the sensitised pain state. Neither alone fully addresses the dual-driver model of central sensitisation. Both approved. This specific combination has never been tested in a controlled trial.
Full mechanistic analysis available under commercial agreement.
Request AccessA drug class developed for a blood cancer identified for refractory lupus via targeted degradation of two transcription factors that master-regulate the differentiation of autoantibody-producing cells. This targeted degradation approach is mechanistically distinct from receptor blockade used by every approved lupus biologic. Early lupus data is emerging; the most severe subtype remains untested despite the mechanistic rationale being directly transferable from the cancer indication.
Full mechanistic analysis available under commercial agreement.
Request AccessAn investigational biologic targets synovial immune cell activation through a pathway entirely distinct from every current approved biologic class, retaining mechanistic activity in patients who have exhausted all approved options. Trial data demonstrates efficacy and tolerability. Not yet approved — the regulatory gap between existing evidence and an approved indication for refractory RA represents the specific commercial opportunity.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved drug, already used for autoimmune conditions and a related acute viral illness, suppresses a persistent inflammatory signalling signature while simultaneously addressing autoantibody-mediated autonomic dysfunction in a significant Long COVID patient subset. Existing approval in the related acute illness establishes safety precedent in the same viral context. No completed trial exists in Long COVID despite the mechanism directly targeting the best-characterised neuroinflammatory pathway.
Full mechanistic analysis available under commercial agreement.
Request AccessA sequential biologic protocol for OIT patients who have failed standard approaches — one biologic neutralises existing antibody during the dangerous dose escalation phase, then a second prevents new antibody production to consolidate durable tolerance during maintenance. The two address different points in the same biological lifecycle. No trial has tested this sequential protocol in refractory patients despite the logic being directly derivable from each drug's established pharmacology.
Full mechanistic analysis available under commercial agreement.
Request AccessA sequential biologic protocol identified for peanut OIT surfaces simultaneously for tree nut OIT — with an even stronger mechanistic argument given the exceptional allergen affinity involved. The transition logic between the two biologics follows identical reasoning. Two conditions, same protocol, stronger case in tree nut. No tree nut-specific sequential biologic trial exists.
Full mechanistic analysis available under commercial agreement.
Request AccessAn investigational drug selectively activates the analgesic signalling pathway while avoiding the pathway responsible for tolerance, dependence, and respiratory depression. No studies exist combining this selective mechanism with fibromyalgia as the primary indication, despite central sensitisation being a direct target of the pathway involved.
Full mechanistic analysis available under commercial agreement.
Request AccessRadiation therapy to the head and neck damages a specific nerve cluster, upregulating a pain-signalling neuropeptide and producing chronic pain in survivors — a population with no mechanism-targeted treatment. No drug in this class has ever been evaluated in radiation-induced pain despite the pathway being directly implicated by the same mechanism the drug already blocks in migraine.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific immune structural change begins forming earlier in MS than previously assumed — not only in progressive disease. One approved biologic depletes peripheral immune cells but cannot penetrate brain tissue; a second crosses the blood-brain barrier and suppresses the compartmentalised inflammation current therapies cannot reach. Combining them early, before this structure consolidates, could alter the long-term trajectory toward progressive MS.
Full mechanistic analysis available under commercial agreement.
Request AccessRhinovirus hijacks a specific cellular recycling process as a replication platform, regardless of which of the 160+ serotypes is causing infection. An approved antihelminthic, delivered intranasally, disrupts this hijacking directly at the nasal epithelium — bypassing the poor oral bioavailability that has limited its systemic use. Zero rhinovirus-specific trials exist.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved lupus biologic is identified specifically for lupus kidney disease in patients with a confirmed, measurable inflammatory signature representing roughly 70% of kidney disease cases — the subgroup where the biologic's mechanism is most active. This complication has not been evaluated as a primary trial endpoint despite the signature being directly measurable and predictive of response. The biomarker-stratified design is immediately actionable.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved diabetes drug activates a metabolic checkpoint that downregulates a growth pathway hyperactive in endometriotic lesions, driving their survival and proliferation in ectopic locations — a vulnerability entirely distinct from the hormonal mechanisms targeted by current treatments. Observational signals exist in patients on this drug for comorbid conditions. No properly powered trial has tested this with endometriosis as the primary endpoint.
Full mechanistic analysis available under commercial agreement.
Request AccessA biologic approved for acute flares of a rare, life-threatening psoriasis subtype is identified for flare prevention as a maintenance therapy paradigm instead. The mechanistic rationale for maintenance use is identical to the acute rationale. No trial has evaluated this drug as maintenance therapy with flare prevention as the primary endpoint — a clinically superior paradigm to reactive treatment.
Full mechanistic analysis available under commercial agreement.
Request AccessAn approved biologic, selective for one inflammatory signal rather than two, is identified for peanut OIT — mechanistically distinct from a broader dual-target biologic already discussed in this archive. One signal drives dropout; the other drives durable tolerance. The selective mechanism suppresses the dropout-driving signal while preserving the tolerance-driving one — potentially producing superior long-term outcomes. Zero peanut OIT trials exist for this drug.
Full mechanistic analysis available under commercial agreement.
Request AccessA selective biologic's mechanism, identified for tree nut OIT, carries a stronger argument than the equivalent peanut finding. A specific tree nut allergen binds immune cells with exceptional affinity, producing disproportionately severe reactions during dose escalation. The selective drug suppresses this while preserving the signal needed for durable tolerance — making the case for selective over broad blockade stronger in tree nut than peanut OIT. Zero tree nut-specific trials exist.
Full mechanistic analysis available under commercial agreement.
Request AccessTen consecutive weeks of convergent signals across independent research groups have produced the highest-scoring finding in the Ouki archive. Adult heart muscle cannot normally divide, making heart attack damage permanent. A partial cellular reprogramming approach transiently restores regenerative capacity without the oncogenic risk of earlier methods. Specific small molecule candidates capable of achieving this without viral delivery were independently confirmed across multiple research groups working without coordination — resolving the primary barrier to clinical translation.
Full mechanistic analysis and compound class intelligence available under commercial agreement.
Request AccessPatients with a specific antibody profile represent a tolerance-resistant subgroup who fail oral immunotherapy at disproportionate rates and currently have no effective treatment pathway. A biologic that acts upstream of antibody production — mechanistically distinct from one acting downstream — could simultaneously reduce the immune priming that drives dose reactions. No trial has tested this stratified approach.
Full mechanistic analysis available under commercial agreement.
Request AccessA newly identified immune cell pathway inside the nerve ganglion where HSV lies dormant appears to control when the virus reactivates — upstream of anything current antivirals touch. Pairing standard antiviral suppression with a compound that blocks this specific reactivation trigger has never been tested, despite each acting on entirely separate targets.
Full mechanistic analysis available under commercial agreement.
Request AccessEven with fully suppressive antiretroviral therapy, a specific inflammatory signal continues to drive long-term comorbidity risk — cognitive, cardiovascular, and metabolic — in virally suppressed patients. An already-approved anti-inflammatory drug class, widely used in other conditions, could directly interrupt this pathway. No trial has yet targeted this specific downstream consequence of viral persistence.
Full mechanistic analysis available under commercial agreement.
Request AccessCurrent hormonal treatments suppress estrogen-driven lesion growth but leave a distinct, nerve-signaling-driven pain component entirely untouched — explaining why many patients get partial relief at best. Combining standard hormonal suppression with an approved drug that modulates this separate neural signalling pathway has zero prior research, despite each targeting a completely separate mechanism.
Full mechanistic analysis available under commercial agreement.
Request AccessFibromyalgia is not one condition but several stable, distinguishable subtypes — and current trials pool them together, which mathematically suppresses any real treatment effect. Matching each subtype to the therapy class best suited to its dominant driver, rather than testing one intervention across everyone, could rescue treatments that previously "failed" only because they were tested in the wrong population.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific class of RA therapy carries a known cardiovascular risk signal affecting millions of current patients. Co-prescribing an inexpensive, already-available cardioprotective drug alongside it — using a validated, non-invasive vascular biomarker as the trial endpoint — could directly mitigate this risk, yet has never been formally tested despite both drugs being in routine use.
Full mechanistic analysis available under commercial agreement.
Request AccessEvery currently approved COPD biologic only works in the eosinophilic subtype — leaving the majority of patients with no biologic option at all. A drug that acts on a shared upstream signal ahead of multiple inflammatory pathways could, in principle, work across both COPD phenotypes. Precision biomarker stratification offers a stronger path forward than prior broad, unstratified attempts in this space.
Full mechanistic analysis available under commercial agreement.
Request AccessA specific, underappreciated complication drives meaningful dropout during peanut oral immunotherapy — currently only treated reactively once symptoms appear. Introducing an already-approved, localized therapy proactively during the highest-risk phase, rather than waiting for the complication to develop, has never been tested despite using existing, well-characterized medications.
Full mechanistic analysis available under commercial agreement.
Request AccessA shared allergenic protein family links reactivity across cashew, pistachio, and walnut — but this cross-reactivity has never been therapeutically exploited. Using a single purified component to desensitize patients to multiple tree nuts simultaneously, rather than treating each allergy separately, could dramatically simplify treatment for the large multi-nut-allergic population.
Full mechanistic analysis available under commercial agreement.
Request AccessA newly validated clinical score can identify Type 2 diabetes patients at high risk of developing heart failure before any symptoms appear. Using this score to enroll high-risk patients into primary prevention with an already-approved cardio-renal protective drug — rather than waiting for heart failure to establish — represents a genuinely new prevention strategy in a population with no current disease-modifying option.
Full mechanistic analysis available under commercial agreement.
Request AccessDamaged heart tissue after a heart attack accumulates aging-related cells that actively suppress the heart's own limited regenerative capacity. Combining an emerging cardiac regeneration technique with agents that clear these regeneration-blocking cells targets two independent, non-overlapping barriers simultaneously — a combination with no prior research despite both approaches being independently validated.
Full mechanistic analysis available under commercial agreement.
Request Access